Corporate | 27 July 2011 07:46
|
STRATEC Biomedical AG / Key word(s): Quarter Results/Regulatory Approval
STRATEC – Growth trajectory confirmed after first six months of 2011
–
Sales of EUR 48.5 million in Q1-Q2/2011
–
EBIT margin increased to 18.7% in Q1-Q2/2011,
–
Consolidated net income of EUR 7.0 million in Q1-Q2/2011
–
Earnings per share of EUR 0.60 in Q1-Q2/2011
Birkenfeld, July 27, 2011 STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) today announced its figures for the period from January 1, 2011 to June 30, 2011 upon the publication of its interim report as of June 30, 2011.
Financial performance
The unwinding of the remaining consumable backlog from the fourth quarter of 2010 has led to a rise in the proportion of sales generated by consumables, resulting in a slightly higher increase in the EBIT margin than originally expected. The EBIT margin rose to 18.7% in the first six months, up from 18.0% in the first quarter of 2011. Consolidated net income increased year-on-year by 14.8% to EUR 7.0 million, and earnings per share increased to EUR 0.60.
Project development
Of the three new contracts expected in 2011, one new development and supply contract has been signed. Additional negotiations are in advanced stages and provide the grounds for us to confirm our previous forecast. Further details concerning these contracts will be published once agreements have been reached with the respective customers.
Other developments
To date, we have experienced no negative impacts from government savings measures or from fiscal policy measures in the euro and US dollar areas on our customers' planned acceptance volumes. Indeed, STRATEC's business model remains largely independent of macroeconomic factors. Furthermore and as previously announced, STRATEC has not witnessed any supplier problems seen in other industries in the wake of the Japanese earthquake crisis.
Development in staff totals
Outlook
Achievement of or potentially exceeding the upper end of sales guidance (EUR 123 million) in 2011 is dependent on the timing of the planned and pending market launches of new systems, which is also determined by their approval in the relevant markets. Further details can be found in our Interim Report as of June 30, 2011 published at www.stratec.com > Investor Relations > IR News > Financial Reports.
About STRATEC
The STRATEC Group consists of the publicly listed parent company STRATEC Biomedical AG and of subsidiaries and second-tier subsidiaries in Germany, the USA, the UK, Switzerland and Romania.
Further information can be obtained from:
End of Corporate News 27.07.2011 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
| Language: | English | |
| Company: | STRATEC Biomedical AG | |
| Gewerbestr. 37 | ||
| 75217 Birkenfeld | ||
| Germany | ||
| Phone: | +49 (0)7082 7916 0 | |
| Fax: | +49 (0)7082 7916 999 | |
| E-mail: | info@stratec.com | |
| Internet: | www.stratec.com | |
| ISIN: | DE0007289001 | |
| WKN: | 728900 | |
| Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart | |
| End of News | DGAP News-Service |
|
|
| 133309 27.07.2011 |